In a recent PROSPECT-C trial on metastatic colorectal cancer (CRC) patients, the aberrations in the RAS pathway and their association with resistance to anti-EGFR treatment in metastatic CRC were investigated. This evidence concerns the gene EGFR and colorectal carcinoma.